Ginkgo biloba L. (Ginkgoaceae) leaf extract is one of the most frequently sold herbal extracts. There have been reports on poor quality and adulteration of ginkgo leaf extracts or the powdered plan...
Airway epithelium repair after infection consists of wound repair, re-synthesis of the extracellular matrix (ECM), and tight junction proteins. In humans, EPs® 7630 obtained from Pelargonium sidoides roots reduces the severity and duration of acute respiratory tract infections. The effect of EPs® 7630 on tissue repair of rhinovirus-16 (RV-16) infected and control human airway epithelial cells was assessed for: (i) epithelial cell proliferation by manual cell counts, (ii) epithelial wound repair by “scratch assay”, (iii) ECM composition by Western-blotting and cell-based ELISA, and (iv) epithelial tight junction proteins by Western-blotting. EPs® 7630 stimulated cell proliferation through cAMP, CREB, and p38 MAPK. EPs® 7630 significantly improved wound repair. Pro-inflammatory collagen type-I expression was reduced by EPs® 7630, while fibronectin was increased. Virus-binding tight junction proteins desmoglein2, desmocollin2, ZO-1, claudin1, and claudin4 were downregulated by EPs® 7630. The RV16-induced shift of the ECM towards the pro-inflammatory type was prevented by EPs® 7630. Most of the effects of EPs® 7630 on tissue repair and regeneration were sensitive to inhibition of cAMP-induced signaling. The data suggest that EPs® 7630-dependent modification of epithelial cell metabolism and function might underlie the faster recovery time from viral infections, as reported by others in clinical studies.
22 March 2023 in ACS Sustainable Chemistry & Engineering
EPs® 7630, a 15% hydroalcoholic Pelargonium sidoides extract, is used for the treatment of common cold, especially bronchitis. Minor ingredients are the plant-characteristic highly oxygenated benzopyranons, like umckalin in free and sulfated form, in addition to the major monomeric and oligomeric (epi)gallocatechins, the prodelphinidins (OPDs). Detailed analysis of purified OPDs with 1D-and 2D-NMR (HSQC, HMPC) revealed a predominant 4->8 B-type connectivity of the monomeric units gallocatechin and epigallocatechin in about equal quantities. In addition to the plain OPD, another oligomer with an unusual additional substitution was detected, which was characterized by an added mass of 111 Da, leading to signals in the positive mass spectrum of (PES [M+H]+: 418, 722, 1026 Da; plain OPD: 307, 611, 915 Da). Isolation of one low content monomeric entity in combination with 2D-NMR spectroscopy revealed a pyrrolidine-1-carboximidamide-2-yl conjugation at the 8-position of (epi)gallocatechins. These substances were not reported yet, and are thus named as sidoamidines. Biomimetic syntheses of four pure isomers starting with (-)-gallocatechin and (-)-epigallocatechin, respectively, made it possible to establish their exact chemical structure by HRESIMS, 2D-NMR, and CD-spectroscopy [Fig. 1]. The chirality of the building blocks was unequivocally demonstrated by chiral chromatography and optical rotation of selected reference material. Separation of the oligomeric sidoamidine fraction from plain OPD by cation exchange chromatography demonstrated quite similar structural characteristics (HSQC spectra) beside the extra substitution. Evaluation of the new components in an animal disease model, the LPS induced sickness behavior, may argue for positive involvement in the (malady) treatment with EPs® 7630.
Summary: Every year, the number of studies that evaluate the pharmacological effects, (clinical) efficacy or the toxicity of medicinal plant extracts is constantly increasing, but the reporting quality remains unsatisfactory. One of the main reasons is that there is a lack of detailed reporting standards for guidance. In response to this long-standing challenge, a core group of nine experts with proficiency in phytochemical analysis, including editors-in-chief of leading specialist journals, and based in different research settings globally, developed the Consensus based reporting guidelines for Phytochemical Characterisation of Medicinal Plant extracts (ConPhyMP) through a multi-staged development process. This incorporated a) a global survey among medicinal plant researchers, b) a core group, who reviewed and developed the guidelines through a Delphi process, and c) an advisory group of 20 experts, including editors of leading journals and scientific societies in medicinal plants research, who provided feedback and sanctioned the final guidelines. The ConPhyMP guidelines comprise two tables with accompanying explanatory figures. The first table provides recommendations for reporting the starting material and its initial processing, and the second table presents recommendations for conducting and reporting the analytical methods for defining the chemical profile based on the type of extracts used in the research. The group hopes that the ConPhyMP will support authors as well as peer reviewers and editors assessing these studies for publication and assist the production of evidence-based guidance of studies utilising medicinal plant extracts.